NOTE

– Share-Based Compensation

2003,

the stockholders of the Company approved the

2003

Incentive Stock and Awards Plan (the

“2003

Plan”), authorizing the granting of incentive stock options, non-qualified stock options, stock appreciation rights (“SARS”), restricted stock, performance shares and other stock based compensation. This plan expired in

May

2013,

at which time, the stockholders of the Company approved the

2013

Incentive Stock and Awards Plan (the

“2013

Plan”), authorizing the granting of incentive stock options, non-qualified stock options, SARS, restricted stock, performance shares and other stock based compensation. A total of

5,000,000

shares of common stock (subject to adjustment for expirations and cancellations of options outstanding from the

2003

Plan subsequent to its termination) have been reserved for issuance under the

2013

Plan. All options and SARS under both plans have been or will be granted with exercise prices at least equal to the fair market value of the shares on the date of grant. At

March 31, 2018,

the Company had

3,507,469

shares of common stock available for grant of share-based compensation under the

2013

Plan.

Share-based compensation is recorded in selling and administrative expense in the consolidated statements of comprehensive income. The following table details the share-based compensation expense by type of award and the total related tax benefit for the periods presented:

	Three Months Ended March 31,
	(In thousands)
	2018		2017
Stock options and SARS	$	823	$	665
Restricted stock		124		134
Performance shares		105		43
Total share-based compensation expense	$	1,052	$	842

Related income tax benefit	$	111	$	334

Stock options and SARS

The Company grants stock options and stock settled SARS to employees that allow them to purchase shares of the Company’s common stock. Options are also granted to outside members of the Board of Directors of the Company. The Company determines the fair value of stock options and SARS at the date of grant using the Black-Scholes valuation model.

All options and SARS vest immediately at the date of grant. Awards generally expire

five

years after the date of grant with the exception of options granted to outside directors, which expire

ten

years after the date of grant. The Company issues new shares upon the exercise of stock options and SARS.

A summary of stock option transactions during the

three

months ended

March 31, 2018

follows:

	No. of			Weighted Average
	Shares			Exercise Price
Outstanding December 31, 2017		633,877		$	13.33
Granted		87,385			23.59
Exercised		(38,908	)		10.35
Lapsed		-			-
Cancelled		(700	)		18.68
Outstanding March 31, 2018		681,654		$	14.81

March 31, 2018,

options outstanding, all of which were fully vested and exercisable, had an aggregate intrinsic value of

$7.8

million. The weighted-average remaining contractual term was

months.

Options exercised during the

three

-month periods ended

March 31, 2018

and

2017

had intrinsic values of

$0.6

million and

$0.6

million, respectively.

The weighted average fair values of the Company’s

87,385

and

90,012

options granted during the

three

-month periods ended

March 31, 2018

and

2017

was

$6.06

and

$4.83,

respectively.

During the

three

-month periods ended

March 31, 2018

and

2017,

respectively, the Company received

$0.3

million and

$0.1

million in cash from stock option exercises. Additionally, during the

three

-month period ended

March 31, 2018

and

2017,

respectively, the Company received

5,863

and

16,500

shares of its common stock as payment of the exercise price in the exercise of stock options for

20,234

and

41,544

shares. The tax benefit recognized for these exercises during the

three

-month periods ended

March 31, 2018

and

2017

was

$0.1

million and

$0.1

million, respectively.

The following table summarizes information about stock options outstanding as of

March 31, 2018:

					Weighted Average
Range of					Remaining		Weighted Average
Exercise Price			Shares		Contractual Life (Years)		Exercise Price
$ 3.82	-	$ 5.88		102,800		2.93	$	5.26
$ 7.36	-	$10.38		128,367		2.04	$	7.88
$16.35	-	$18.66		316,017		3.40	$	17.28
$21.63	-	$23.59		134,470		4.66	$	22.90

$3.82	-	$23.59		681,654		3.32	$	14.81

A summary of stock-settled SARS transactions during the

three

months ended

March 31, 2018

follows:

	No. of			Weighted Average
	Shares			Exercise Price
Outstanding December 31, 2017		146,504		$	17.38
Granted		48,515			23.59
Exercised		(12,125	)		17.92
Lapsed		-			-
Cancelled		-			-
Outstanding March 31, 2018		182,894		$	18.99

March 31, 2018,

SARS outstanding, all of which were fully vested and exercisable, had an aggregate intrinsic value of

$1.3

million. The weighted-average remaining contractual term was

months.

The weighted average fair values of the Company’s

48,515

and

43,988

SARS granted during each of the

three

-month periods ended

March 31, 2018

and

2017

was

$6.06

and

$4.83,

respectively.

There were

12,125

and

59,364

SARS exercised during the

three

-month periods ended

March 31, 2018

and

2017,

respectively. SARS exercised during the

three

-month periods ended

March 31, 2018

and

2017

had intrinsic values of

$0.1

million and

$0.7

million, respectively. The tax benefit recognized for these exercises during each of the

three

-month periods ended

March 31, 2018

and

2017

was

$0.1

million and

$0.2

million, respectively.

The following table summarizes information about SARS outstanding as of

March 31, 2018:

					Weighted Average
Range of					Remaining		Weighted Average
Exercise Price			Shares		Contractual Life (Years)		Exercise Price
$16.35	-	$18.66		134,379		2.83	$	17.33
$23.59	-	$23.59		48,515		4.83	$	23.59

$16.35	-	$23.59		182,894		3.36	$	18.99

Options and SARS have never been repriced by the Company in any year.

The following table summarizes significant assumptions utilized to determine the fair value of options and SARS.

Three months ended
March 31,	SARS			Options

Exercise price
2018	$	23.59		$	23.59
2017	$	16.97		$	16.97

Market price
2018	$	23.59		$	23.59
2017	$	16.97		$	16.97

Risk free interest rate 1
2018		2.6	%		2.6	%
2017		1.9	%		1.9	%

Expected award life (years) 2
2018		3			3
2017		5			5

Expected volatility 3
2018		38.1	%		38.1	%
2017		36.6	%		36.6	%

Expected dividend yield 4
2018		1.6	%		1.6	%
2017		2.1	%		2.1	%

The risk-free interest rate is based on the yield of a U.S. treasury bond with a similar maturity as the expected life of the awards.

The expected life in years for awards granted was based on the historical exercise patterns experienced by the Company when the award is made.

The determination of expected stock price volatility for awards granted in each of the periods ending

March 31, 2018

and

2017

was based on historical Superior common stock prices over a period commensurate with the expected life.

The dividend yield assumption is based on the history and expectation of the Company’s dividend payouts.

Restricted Stock

The Company has granted restricted stock to directors and certain employees under the terms of the

2013

Plan which vest at a specified future date, generally after

three

years, or when certain conditions are met. The shares are subject to accelerated vesting under certain circumstances as outlined in the

2013

Plan. Expense for each of these grants is based on the fair value at the date of the grant and is being recognized on a straight-line basis over the respective service period. As of

March 31, 2018,

the Company had

$1.2

million of unrecognized compensation cost related to nonvested grants expected to be recognized over the weighted average service period of

2.08

years.

A summary of restricted stock transactions during the

three

months ended

March 31, 2018

follows:

			Weighted Average
	No. of		Grant Date
	Shares		Fair Value
Outstanding December 31, 2017		61,378	$	17.89
Granted		24,908		23.56
Vested		-		-
Forfeited		-		-
Outstanding March 31, 2018		86,286	$	19.52

Performance Shares

In the quarter ended

March 31, 2018,

the Compensation Committee of the Board of Directors approved grants of performance shares under the terms of the

2013

Plan. Under the terms of the grants, certain employees received service-based or service-based and performance-based shares. The service-based awards vest after the service period is met, which is generally

three

five

years. Expense for these grants is based on the fair value on the date of the grant and is being recognized on a straight-line basis over the respective service period. The performance-based shares generally vest after

five

years if the performance and service targets are met. The Company evaluates the performance conditions associated with these grants each reporting period to determine the expected number of shares to be issued. Based upon this evaluation, expected expenses for these grants are based on the fair value on the date of the grant are being recognized on a straight-line basis over the respective service period. The shares are subject to accelerated vesting under certain circumstances as outlined in the

2013

Plan. As of

March 31, 2018,

the Company had

$1.5

million of unrecognized compensation cost related to nonvested grants expected to be recognized over the weighted average service period of

3.00

years.

A summary of performance share transactions during the

three

months ended

March 31, 2018

follows:

			Weighted Average
	No. of		Grant Date
	Shares		Fair Value
Outstanding December 31, 2017		118,492	$	17.24
Granted		2,778		26.99
Vested		-		-
Forfeited		-		-
Outstanding March 31, 2018		121,270	$	17.46